Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
Daewoong Pharmaceutical, HanAll Biopharma join Astellas Venture Management and other VCs in oversubscribed funding round to accelerate Turn Bio's preclinical advances in multiple therapeutic areas
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Essent continues to broaden its highly characterized, low passage primary cell catalog
Subscribe To Our Newsletter & Stay Updated
